Skip to main content

Featured

The CUSMA Countdown: 24 Days to a Trade Deadline That Could Hit Your Wallet

Canada's free trade deal with the U.S. hits a mandatory review milestone on July 1. With negotiations unresolved and Washington demanding changes, here's what it actually means for your groceries, your car, and your job. MoneySavings.ca Staff Canadian Money Brief June 7, 2026 5 min read What Is CUSMA and Why Does July 1 Matter? CUSMA — the Canada-United States-Mexico Agreement — is the trade deal that keeps the North American economy humming. It replaced NAFTA in 2020 and governs the movement of trillions of dollars in goods and services across the Canada-U.S. border every year. For Canadian consumers, it's largely invisible — until it isn't. Built into the agreement is a mandatory six-year joint review, and that clock expires on July 1, 2026 . By that date, all three countries must declare whether they want to renew the deal for another 16 years, trigger annual reviews, or walk away. Whatever they decide, CUSMA technically stays in force until 2036 — but the path chose...
Post a Comment
Read more

article

Labels

Alzheimer’s vaccines get a boost from new drug approval

 

After decades of disappointment and controversy, the field of Alzheimer’s disease research has finally seen a breakthrough with the approval of the first drug that targets the underlying pathology of the condition. 

Aducanumab, a monoclonal antibody that clears amyloid plaques from the brain, was granted accelerated approval by the US Food and Drug Administration in June 2021, despite mixed results from clinical trials and objections from some experts. 

The drug’s approval has rekindled interest in other therapeutic approaches that aim to prevent or slow down the progression of Alzheimer’s, such as vaccines that stimulate the immune system to attack amyloid or tau, another protein that accumulates in the brains of people with the disease. 

Several vaccine candidates are currently in various stages of development and testing, and some researchers are optimistic that they could offer a more effective and convenient way to treat Alzheimer’s than infusions of antibodies.


Labels:

Comments

Post a Comment